Evamist is owned by Padagis Us.
Evamist contains Estradiol.
Evamist has a total of 1 drug patent out of which 1 drug patent has expired.
Expired drug patents of Evamist are:
Evamist was authorised for market use on 27 July, 2007.
Evamist is available in spray;transdermal dosage forms.
The generics of Evamist are possible to be released after 31 July, 2022.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US6978945||PADAGIS US||Dispensing device|| |
(6 months ago)
Market Authorisation Date: 27 July, 2007
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic